CagriSema vs Orforglipron: Max Efficacy Injection vs Affordable Oral Pill

CagriSema vs Orforglipron: Max Efficacy Injection vs Affordable Oral Pill

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice. Weight loss medications require a prescription and ongoing medical supervision. Discuss all treatment decisions with your healthcare provider, who can evaluate your individual health history, medications, and goals.

April 2026 context: CagriSema NDA filed December 2025 — FDA decision expected Q4 2026. Orforglipron PDUFA date April 10, 2026 — not yet approved. Medicare Bridge for obesity GLP-1s pending Congressional action.

CagriSema and orforglipron represent two fundamentally different answers to the same question: what comes after first-generation GLP-1 medications? CagriSema pursues maximum weight loss by combining two hormones in a weekly injection. Orforglipron pursues accessibility — a daily pill at a fraction of the cost of injectable options.

The critical context: orforglipron is pending FDA approval (PDUFA expected April 2026) and expected through LillyDirect and telehealth providers post-approval at $149-399 per month. CagriSema is not yet approved. Novo Nordisk filed the NDA in December 2025 with no PDUFA date publicly disclosed; a decision is expected in late 2026 or 2027. For patients deciding between these two medications, availability timing is the first and most important difference.

This guide compares mechanisms, clinical data, side effects, cost, and access so you can have an informed conversation with your provider about what makes sense for your situation. For a deeper look at CagriSema, see our CagriSema patient guide. For orforglipron details, see our orforglipron guide.

Quick Comparison Table

Factor	CagriSema (Novo Nordisk)	Orforglipron (Eli Lilly)
Generic name	Cagrilintide 2.4mg + semaglutide 2.4mg	Orforglipron
Mechanism	GLP-1 + amylin (dual hormone)	GLP-1 receptor agonist (single)
Administration	Weekly subcutaneous injection	Daily oral pill
Key trial	REDEFINE program	ATTAIN program
Weight loss (vs placebo)	22.7% at 68 weeks (REDEFINE-1)	~14-15% at highest dose, 72 weeks (ATTAIN)
Head-to-head vs tirzepatide	22.2% vs 25.3% — failed non-inferiority (REDEFINE-4)	Not tested head-to-head
FDA status	Not approved (NDA filed Dec 2025, under review)	Pending FDA approval (expected April 2026)
Availability	Not available	Available now
Cash pay price	Unknown (expected $1,000+/mo list)	$149/mo (lowest dose) to $399/mo (highest dose) via LillyDirect
Medicare	TBD	$50/mo
Nausea rate	40-45%	59% (ACHIEVE-1)
Food restrictions	None (injection)	None
Fasting required	No	No

How do CagriSema and orforglipron work differently?

CagriSema stacks two appetite-suppression hormones — GLP-1 and amylin — in a single weekly injection. Orforglipron delivers one (GLP-1) in an oral daily pill format. The dual mechanism explains CagriSema's higher efficacy; the oral delivery explains orforglipron's accessibility advantage.

CagriSema and orforglipron reduce appetite through different biological strategies. Understanding the mechanism difference helps explain the efficacy gap — and why these medications serve genuinely different patient populations.

CagriSema: Dual Hormone Approach

CagriSema combines two drugs in a single weekly injection:

Semaglutide 2.4mg is the same GLP-1 receptor agonist in Wegovy and Ozempic. It suppresses appetite by acting on brain regions controlling hunger, slows gastric emptying, and improves blood sugar regulation. Semaglutide has the most extensive clinical track record of any obesity medication, including cardiovascular outcome data from the SELECT trial.

Cagrilintide 2.4mg is a long-acting analog of amylin, a hormone the pancreas releases alongside insulin after meals. Amylin suppresses appetite through brain pathways distinct from GLP-1 — primarily the area postrema and hypothalamus. The rationale: stacking two appetite-suppression systems should produce more weight loss than either alone.

The combination produced strong results in REDEFINE-1 (22.7% weight loss), but the dual-hormone approach has a notable limitation. In the REDEFINE-4 head-to-head trial against tirzepatide, CagriSema failed to prove non-inferiority — meaning GLP-1 plus amylin did not match GLP-1 plus GIP.

Orforglipron: Oral GLP-1

Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. Unlike injectable GLP-1 medications (which are peptides that would be destroyed by stomach acid), orforglipron is a chemically engineered small molecule that can survive oral delivery. This is why it works as a daily pill.

Orforglipron activates a single receptor — GLP-1 — to suppress appetite, slow gastric emptying, and improve metabolic markers. It targets one pathway rather than two, which likely explains the lower weight loss compared to dual-mechanism medications like CagriSema or tirzepatide.

A meaningful practical advantage: unlike oral semaglutide (Wegovy pill), orforglipron does not require fasting. You can take it at any time without food restrictions, which removes a significant compliance barrier.

Why the Mechanism Difference Matters

CagriSema stacks two appetite-suppression hormones (GLP-1 + amylin). Orforglipron delivers one (GLP-1) in a highly accessible oral form. The trade-off is clear: CagriSema produces more weight loss in clinical trials, but orforglipron offers the convenience of a pill and dramatically lower cost. These are not competing for the same patient — they solve different problems. Patients asking "CagriSema vs orforglipron which is better" are really asking which trade-off they prefer.

How do CagriSema and orforglipron compare on weight loss?

CagriSema produced 22.7% weight loss at 68 weeks in REDEFINE-1; orforglipron produced approximately 14-15% at 72 weeks in the ATTAIN trials. That roughly 8 percentage point gap reflects the difference between a dual-hormone and single-hormone mechanism — but these medications were never tested head-to-head.

Metric	CagriSema (REDEFINE-1)	Orforglipron (ATTAIN)
Trial duration	68 weeks	72 weeks
Population	Adults with obesity, no diabetes	Adults with obesity, no diabetes
Weight loss (vs placebo)	22.7%	~14-15% (36mg dose)
Placebo weight loss	~3%	~2-3%
Head-to-head vs tirzepatide	22.2% vs 25.3% (failed non-inferiority)	Not tested

Important Caveats About These Numbers

These are cross-trial comparisons. CagriSema and orforglipron have not been tested head-to-head. The REDEFINE and ATTAIN programs enrolled different patient populations, used different protocols, and measured outcomes at slightly different timepoints. Cross-trial comparisons are directionally useful but not definitive.

The gap is real, but the context matters. The roughly 8 percentage point difference (22.7% vs ~14-15%) is large enough that trial design differences alone are unlikely to explain it. CagriSema's dual-hormone mechanism genuinely appears to produce more weight loss than a single GLP-1 agonist. But more weight loss is not the only variable that matters — access, cost, and route of administration all factor into real-world outcomes.

CagriSema lost to tirzepatide. In REDEFINE-4, CagriSema produced 22.2% weight loss compared to tirzepatide's 25.3% and failed to prove non-inferiority. This is relevant because tirzepatide (as Zepbound) is already available. Patients seeking maximum efficacy from an injectable already have an option that outperformed CagriSema in a head-to-head trial.

The ATTAIN-MAINTAIN Story

One of the most clinically relevant data points for this comparison comes from Eli Lilly's ATTAIN-MAINTAIN trial. This study examined what happens when patients switch from injectable GLP-1 medications to orforglipron:

• Patients switching from Wegovy to orforglipron maintained their weight loss with only a 0.9kg difference
• Patients switching from Zepbound to orforglipron showed a 5.0kg difference — more weight regain, but still substantial maintenance

This matters because it suggests a practical treatment pathway: start with an injectable for maximum initial weight loss, then transition to an affordable oral option for long-term maintenance. It also suggests that patients who start orforglipron now could potentially switch to CagriSema later if it offers specific advantages for their situation.

How do CagriSema and orforglipron compare on side effects?

Both medications cause substantial GI side effects, but orforglipron's nausea rate (59%) is notably higher than CagriSema's (40-45%). CagriSema adds injection site reactions as a side effect that orforglipron users will never face.

Side Effect	CagriSema	Orforglipron
Nausea	40-45%	59% (ACHIEVE-1)
Diarrhea	25-30%	Comparable to other GLP-1s
Vomiting	Common (rate varies by trial)	Common
Injection site reactions	Yes	N/A (oral)
Discontinuation rate	Moderate	Moderate
Food timing requirements	None	None

GI Side Effects: Both Are Significant

Both medications cause substantial gastrointestinal side effects. This is inherent to GLP-1 receptor activation — slowing gastric emptying and suppressing appetite produces nausea, particularly during dose titration.

Orforglipron's nausea rate of 59% in the ACHIEVE-1 trial is notably higher than most injectable GLP-1 medications. This may reflect the daily dosing pattern (constant GLP-1 stimulation rather than weekly peaks and troughs) or the specific pharmacokinetics of oral delivery. In clinical practice, GI side effects typically diminish over 4-8 weeks as the body adapts.

CagriSema's nausea rate of 40-45% is more in line with other injectable GLP-1 medications, though the addition of cagrilintide adds injection site reactions as a side effect that orforglipron users will never experience.

Route of Administration

This is a meaningful quality-of-life difference. Orforglipron is a daily pill — no needles, no injection site reactions, no cold chain storage requirements. For patients with needle anxiety or who travel frequently, this is a significant practical advantage.

CagriSema requires weekly subcutaneous injections. Some patients prefer the weekly routine to a daily pill. Neither is objectively better — it depends on individual preference.

How do CagriSema and orforglipron compare on cost and access?

This is where the comparison becomes most stark. Orforglipron at $149-399/month through LillyDirect is available now; CagriSema has no approved price and no firm launch date. For patients asking "cheapest way to get semaglutide online" or looking for an affordable GLP-1 without insurance, orforglipron is currently the clear answer.

Cost Factor	CagriSema	Orforglipron
List price	Unknown (expected $1,000+/mo)	N/A (DTC pricing)
Cash pay	Unknown	$149/mo (lowest dose) to $399/mo (highest dose)
Medicare	TBD	$50/mo
Insurance coverage	TBD (likely similar to Wegovy challenges)	Varies; LillyDirect bypasses insurance
Savings programs	Expected at launch	Included in LillyDirect pricing
Availability	Not available	Available now via LillyDirect and telehealth providers

Orforglipron's Price Advantage Is Massive

Orforglipron at $149-399 per month through LillyDirect — and $50 per month on Medicare — represents a fundamentally different cost tier than any Novo Nordisk obesity product to date. Wegovy lists at over $1,300 per month. CagriSema, as a next-generation combination product from the same company, is expected to command a premium price. Even with savings programs, the out-of-pocket difference is likely to be hundreds of dollars per month.

For the millions of patients who have been priced out of GLP-1 therapy, orforglipron is the first branded option that approaches affordability without insurance. CagriSema, whenever it launches, will almost certainly require insurance coverage or manufacturer savings programs to be financially accessible for most patients.

Availability Is Not a Minor Detail

CagriSema is not FDA approved. The NDA was filed in December 2025, and no PDUFA date has been publicly disclosed. A decision is expected in late 2026 or 2027, but regulatory timelines can shift. What we know is that CagriSema cannot be prescribed today, and no firm launch date exists.

Orforglipron is available now. You can get a prescription through LillyDirect or through telehealth providers that prescribe weight loss medications. Treatment can begin this week.

Who should consider CagriSema vs orforglipron?

These medications solve different problems. Orforglipron is for patients who want to start treatment now at an affordable price in pill form. CagriSema — once approved — is for patients who need maximum injectable efficacy and have already tried single-mechanism GLP-1 drugs.

CagriSema May Be Worth Waiting For If You:

• Have not responded adequately to single-mechanism GLP-1 medications (semaglutide or liraglutide alone)
• Are specifically interested in the amylin pathway and have discussed this with your provider
• Have insurance that will likely cover it at launch
• Are not in urgent need of weight loss treatment for health reasons
• Have already tried tirzepatide and want to explore alternatives

Important caveat: CagriSema failed to beat tirzepatide in REDEFINE-4. If you are seeking maximum efficacy from an injectable, tirzepatide (Zepbound) is available now with stronger head-to-head data.

Orforglipron Makes Sense If You:

• Want to start treatment now rather than wait for an uncertain approval timeline
• Prefer an oral medication over injections
• Are paying out of pocket and need an affordable option
• Are on Medicare ($50/mo is the lowest GLP-1 price available)
• Want a medication you can take without fasting requirements
• Are looking for a maintenance option after initial weight loss on an injectable

Should you wait for CagriSema or start orforglipron now?

For most patients, the answer is clear: start orforglipron now. The ATTAIN-MAINTAIN trial shows you can switch medications later without losing progress, and every month without treatment carries real metabolic cost.

This is the question many patients are asking, and the answer is clearer than it might seem.

Start orforglipron now if treatment is clinically appropriate. Every month without treatment is a month of continued obesity-related metabolic risk. The ATTAIN-MAINTAIN data show that switching between GLP-1 medications is viable — starting orforglipron does not lock you into a permanent choice.

The math on waiting does not favor CagriSema for most patients. CagriSema's approval timeline is uncertain. Even after approval, insurance coverage will take months to establish, supply chains will need to ramp up, and real-world pricing may not be immediately clear. Patients who wait could realistically be looking at 6-12+ months before they can actually fill a CagriSema prescription — and that assumes approval happens soon.

The efficacy gap, while real, must be weighed against months of no treatment. CagriSema's 22.7% weight loss is impressive. But a patient who starts orforglipron today and achieves 14-15% weight loss over the next year will be in a meaningfully better metabolic position than a patient who waited and has yet to start any treatment.

You can switch later. If CagriSema is approved and offers specific advantages for your clinical situation, you and your provider can make that transition. The ATTAIN-MAINTAIN trial provides reassurance that GLP-1 medication switching is feasible without losing all progress.

The Exception

If you have already tried multiple GLP-1 medications without adequate response and your provider specifically believes the amylin mechanism may help, waiting for CagriSema could be reasonable. This is a narrow clinical scenario, not the default recommendation.

Frequently Asked Questions

Is CagriSema better than orforglipron?

CagriSema showed higher weight loss in clinical trials (22.7% vs ~14-15%), but these medications have never been compared head-to-head. CagriSema uses a dual-hormone mechanism while orforglipron is a single GLP-1 agonist. "Better" depends on what you are optimizing for: CagriSema appears to produce more weight loss, but orforglipron has an imminent PDUFA date (April 10, 2026) at $149/month, and comes in pill form. Neither is FDA-approved yet; CagriSema's approval timeline is more uncertain.

Should I wait for CagriSema or start orforglipron now?

For most patients, starting available treatment is better than waiting for an uncertain timeline. Orforglipron is awaiting FDA approval (PDUFA April 10, 2026) and is expected through LillyDirect and telehealth providers at $149/month. Once available, the ATTAIN-MAINTAIN trial data suggests patients can switch between GLP-1 medications while maintaining weight loss — so starting orforglipron does not prevent you from trying CagriSema later.

Can I switch from orforglipron to CagriSema later?

While no direct orforglipron-to-CagriSema switching trial exists, the ATTAIN-MAINTAIN trial demonstrated that patients can transition between different GLP-1 medications while maintaining weight loss. Switching would be a clinical decision made with your provider based on your response to orforglipron, your goals, and CagriSema's availability and cost at that time.

Why did CagriSema fail against tirzepatide in REDEFINE-4?

In REDEFINE-4, CagriSema produced 22.2% weight loss compared to tirzepatide's 25.3% and failed to prove non-inferiority. The GLP-1 + GIP mechanism (tirzepatide) appears to produce more weight loss than GLP-1 + amylin (CagriSema), possibly because GIP receptor activation provides metabolic benefits that amylin does not replicate. This does not mean CagriSema is ineffective — 22% weight loss is clinically meaningful — but it did not match tirzepatide.

Is orforglipron as effective as injectable GLP-1 medications?

Orforglipron produces less weight loss than the most effective injectables. At ~14-15% in the ATTAIN trials, it falls below tirzepatide (~21-25%) and semaglutide 2.4mg (~15-17%). However, orforglipron's convenience (daily pill, no fasting) and cost ($149-399/mo) make it a viable option for patients who would not otherwise access GLP-1 therapy. Some weight loss with treatment is always better than theoretical maximum weight loss without it.